Second is Eli Lilly (LLY), the best of the highest-yielding drug stocks and one that I find could have an acceleration in earnings. The ImClone deal looks like a good one, even as initially I thought they paid too much.

No Bloom for Lilly: The Mad About Options crew reviews Jim Cramer's recent bullish comments about Eli Lilly and offers options strategies for traders and investors.
Click here to watch the video.

From a recent Mad Money show:"I think the government is taking aim at big pharma. So anyone like Lily is going to have prices driven down. That's a big change for me, but I can't recommend them."

From a recent Mad Money show:"I think the government is taking aim at big pharma. So anyone like Lily is going to have prices driven down. That's a big change for me, but I can't recommend them."

The drug sector is well represented with industry leaders Merck, Bristol-Myers, Lilly and Pfizer. Dividends at all four look secure, although future payout increases could be muted by modest annual profit growth. The new Pfizer dividend of 64 cents annually, for a 4.5% yield, looks safe at just 30% of projected 2009 earnings. The negative investor reaction to the Pfizer payout cut may make other drug makers wary of reducing dividends.

How about how the market shrugs off the Lilly (LLY) approval of a Plavix killer -- bread-and-butter for Bristol (BMY) --and takes up BMY anyway!

lots of cash

2:30

future growth

Boeing's Dividend Is Bogus: David Peltier, portfolio manager of Dividend Stock Advisory, tells you which dividend raises of 2008 are smart and which ones are dangerous.
Click here to watch the video.

Pharma will drop with next President

Don't like pharmaceuticals

Losing market share quickly

"Lilly shares look like dead money following a mixed test result for its experimental anticlotting drug. They could drop another 10% if the product doesn't generate sales."

short

too many stumbles